Abstract
In spite of administration with combined chemotherapy, more than half of patients fall into the refractory status in hematological malignancy. Various cellular and molecular markers suggesting the independent prognostic factors were identified and utilized as subclassification of refractory cases. We demonstrated that cyclinD1 over-expression in mantle cell lymphoma and CD5 positive expression in diffuse large B-cell lymphoma, which should be recommended myeloablative therapy in early phase, show distinct, significantly poor prognostic factors. Using personal molecular and cellular profiles including drug sensitivity, order-made medicine might be offered for each individual patient as an optimal therapeutic strategy.
